Pharma & Human Health
-
-
Editor's Choice -
Pharma & Human Health -
Finance -
Pharma & Human Health
Editor’s Choice
Editor's Choice
Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
Abstract Microbiome drug development has captured significant interest over the last decade. However, despite the recent clinical and regulatory success stories, this area is lately regarded as a high-risk one by investors given the current […]
Editor's Choice
DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
Historically, researchers have surveyed the composition and/or expression of microorganisms within the human gut microbiome by collecting fecal samples, isolating microbial nucleic acids, and using those nucleic acids to analyze the microbial species present within […]
Editor's Choice
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults […]
In Case you Missed it:
Pharma & Human Health
Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds
Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut microbiota of individuals with mild anxiety. The positive influence of Cerebiome® on the gut microbiota […]
Pharma & Human Health
Exhaled breath can reveal crucial insight into the microbiome
The microbiome challenges what it means to be an individual. Our understanding of the factors that contribute to health and disease has been revolutionized by the discovery that the human body is colonized by an […]
Editor's Choice
DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
Historically, researchers have surveyed the composition and/or expression of microorganisms within the human gut microbiome by collecting fecal samples, isolating microbial nucleic acids, and using those nucleic acids to analyze the microbial species present within […]
Finance
Solarea Bio Announces First Close of Series B Financing Round
Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of […]
Finance
SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces that Nature Biotechnology has published research findings from its preclinical work on SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and […]
Uncategorized
New discovery stops bacterial virus contamination
A new discovery by researchers at the University of Warwick could help stop bacteria being contaminated with viruses, reducing disruption and decreasing costs in industry and research. Bacteria are routinely used in biological and biomedical […]
Finance
Recipharm will manufacture VOWST on behalf of Seres Therapeutics
Recipharm, a global contract development and manufacturing organization (CDMO), has announced today that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US Food and Drug Administration (FDA) as a manufacturing site of VOWST, a […]
Pharma & Human Health
FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that the U.S. Food and […]
